{"id":"W4412956201","doi":"10.1158/1535-7163.mct-24-1176","title":"Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody–Drug Conjugate","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"FSD Pharma (Canada)","funders":"National Applied Research Laboratories","keywords":"Pharmacology; Medicine; Pharmacokinetics; In vivo; Toxicity; Pharmacodynamics; Drug; Antibody; Cancer research; Cell culture; Immunology; Internal medicine; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003095533,0.0004653202,0.0003775588,0.0002326241,0.0001489979,0.0003076278,0.0002464842,0.0002884494,0.001268361],"category_scores_gemma":[0.0002877904,0.0001917406,0.0002631242,0.0002755625,0.0002261252,0.0003323672,0.0001363449,0.0008669111,0.000331075],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004010738,"about_ca_system_score_gemma":0.0004762069,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007893156,"about_ca_topic_score_gemma":0.0007555733,"domain_scores_codex":[0.9998652,0.00003049724,0.000009080164,0.00002223269,0.00003944672,0.00003358301],"domain_scores_gemma":[0.9998673,0.00001785974,0.00004155393,0.00001445898,0.00002636572,0.00003245691],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.009629121,0.003853057,0.002809754,0.0002230812,0.0001109374,0.0002612637,0.0001049924,0.004226208,0.9423801,0.0003052941,0.001175728,0.0349204],"study_design_scores_gemma":[0.00119954,0.06580321,0.01540067,0.0000229306,0.0003083799,0.001236245,0.00008243172,0.01120806,0.8889583,0.0002005439,0.01553428,0.00004543438],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931861,0.001366766,0.00256717,0.000107839,0.00002924027,0.0001984619,0.000722889,0.00006610274,0.001755529],"genre_scores_gemma":[0.9937309,0.001088425,0.001404129,0.00008622952,0.00002177061,0.0001601742,0.001401887,0.00002737442,0.002079176],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001268361,"threshold_uncertainty_score":0.004243076,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03920731020912873,"score_gpt":0.4259494892401876,"score_spread":0.3867421790310588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}